Federal Register / Vol. 86, No. 34 / Tuesday, February 23, 2021 / Notices 10969 

Task Hourly rate Burden hours Labor cost 

Total ...................................................................................................................................... ........................ ........................ 280,335,935 

Staff believes that there are no current 

start-up costs or other capital costs 

associated with the Textile Rules. 

Because the labeling of textile products 

has been an integral part of the 

manufacturing process for decades, 

manufacturers have in place the capital 

equipment necessary to comply with the 

Rules’ labeling requirements. Industry 

sources indicate that much of the 

information required by the Textile Act 

and Rules would be included on the 

product label even absent their 

requirements. Similarly, recordkeeping, 

invoicing, and advertising disclosures 

are tasks performed in the ordinary 

course of business; therefore, covered 

firms would incur no additional capital 

or other non-labor costs as a result of the 

Rules. 

Request for Comments 

Pursuant to Section 3506(c)(2)(A) of 

the PRA, the FTC invites comments on: 

(1) Whether the proposed collection of 

information is necessary for the proper 

performance of the functions of the 

agency, including whether the 

information will have practical utility; 

(2) the accuracy of the agency’s estimate 

of the burden of the proposed collection 

of information, including the validity of 

the methodology and assumptions used; 

(3) ways to enhance the quality, utility, 

and clarity of the information to be 

collected; and (4) ways to minimize the 

burden of maintaining records and 

providing disclosures to consumers. All 

comments must be received on or before 

April 26, 2021. 

You can file a comment online or on 

paper. For the FTC to consider your 

comment, we must receive it on or 

before April 26, 2021. Write ‘‘Textile 

Rules; PRA Comment: FTC File No. 

P072108’’ on your comment. Your 

comment—including your name and 

your state—will be placed on the public 

record of this proceeding, including the 

https://www.regulations.gov website. 

Due to the public health emergency in 

response to the COVID–19 outbreak and 

the agency’s heightened security 

screening, postal mail addressed to the 

Commission will be subject to delay. We 

encourage you to submit your comments 

online through the https://

www.regulations.gov website. 

If you prefer to file your comment on 

paper, write ‘‘Textile Rules; PRA 

Comment: FTC File No. P072108’’ on 

your comment and on the envelope, and 

mail your comment to the following 

address: Federal Trade Commission, 

Office of the Secretary, 600 

Pennsylvania Avenue NW, Suite CC– 

5610 (Annex J), Washington, DC 20580; 

or deliver your comment to the 

following address: Federal Trade 

Commission, Office of the Secretary, 

Constitution Center, 400 7th Street SW, 

5th Floor, Suite 5610 (Annex J), 

Washington, DC 20024. If possible, 

submit your paper comment to the 

Commission by courier or overnight 

service. 

Because your comment will become 

publicly available at https://

www.regulations.gov, you are solely 

responsible for making sure that your 

comment does not include any sensitive 

or confidential information. In 

particular, your comment should not 

include any sensitive personal 

information, such as your or anyone 

else’s Social Security number; date of 

birth; driver’s license number or other 

state identification number, or foreign 

country equivalent; passport number; 

financial account number; or credit or 

debit card number. You are also solely 

responsible for making sure that your 

comment does not include any sensitive 

health information, such as medical 

records or other individually 

identifiable health information. In 

addition, your comment should not 

include any ‘‘trade secret or any 

commercial or financial information 

which . . . . is privileged or 

confidential’’ —as provided by Section 

6(f) of the FTC Act, 15 U.S.C. 46(f), and 

FTC Rule 4.10(a)(2), 16 CFR 4.10(a)(2) 

—including in particular competitively 

sensitive information such as costs, 

sales statistics, inventories, formulas, 

patterns, devices, manufacturing 

processes, or customer names. 

Comments containing material for 

which confidential treatment is 

requested must be filed in paper form, 

must be clearly labeled ‘‘Confidential,’’ 

and must comply with FTC Rule 4.9(c). 

In particular, the written request for 

confidential treatment that accompanies 

the comment must include the factual 

and legal basis for the request, and must 

identify the specific portions of the 

comment to be withheld from the public 

record. See FTC Rule 4.9(c). Your 

comment will be kept confidential only 

if the General Counsel grants your 

request in accordance with the law and 

the public interest. Once your comment 

has been posted publicly at 

www.regulations.gov, we cannot redact 

or remove your comment unless you 

submit a confidentiality request that 

meets the requirements for such 

treatment under FTC Rule 4.9(c), and 

the General Counsel grants that request. 

The FTC Act and other laws that the 

Commission administers permit the 

collection of public comments to 

consider and use in this proceeding, as 

appropriate. The Commission will 

consider all timely and responsive 

public comments that it receives on or 

before April 26, 2021. For information 

on the Commission’s privacy policy, 

including routine uses permitted by the 

Privacy Act, see https://www.ftc.gov/ 

site-information/privacy-policy. 

Josephine Liu, 

Assistant General Counsel for Legal Counsel. 

[FR Doc. 2021–03604 Filed 2–22–21; 8:45 am] 

BILLING CODE 6750–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Centers for Disease Control and 

Prevention 

[30-Day–21–0888] 

Agency Forms Undergoing Paperwork 

Reduction Act Review 

In accordance with the Paperwork 

Reduction Act of 1995, the Centers for 

Disease Control and Prevention (CDC) 

has submitted the information 

collection request titled Factors 

Influencing the Transmission of 

Influenza to the Office of Management 

and Budget (OMB) for review and 

approval. CDC previously published a 

‘‘Proposed Data Collection Submitted 

for Public Comment and 

Recommendations’’ notice on October 

13, 2020 to obtain comments from the 

public and affected agencies. CDC 

received two comments related to the 

previous notice. This notice serves to 

allow an additional 30 days for public 

and affected agency comments. 

CDC will accept all comments for this 

proposed information collection project. 

The Office of Management and Budget 

is particularly interested in comments 

that: 

(a) Evaluate whether the proposed 

collection of information is necessary for the 

proper performance of the functions of the 

agency, including whether the information 

will have practical utility; 

(b) Evaluate the accuracy of the agencies 

estimate of the burden of the proposed 

10970 Federal Register / Vol. 86, No. 34 / Tuesday, February 23, 2021 / Notices 

collection of information, including the 

validity of the methodology and assumptions 

used; 

(c) Enhance the quality, utility, and clarity 

of the information to be collected; 

(d) Minimize the burden of the collection 

of information on those who are to respond, 

including, through the use of appropriate 

automated, electronic, mechanical, or other 

technological collection techniques or other 

forms of information technology, e.g., 

permitting electronic submission of 

responses; and 

(e) Assess information collection costs. 

To request additional information on 

the proposed project or to obtain a copy 

of the information collection plan and 

instruments, call (404) 639–7570. 

Comments and recommendations for the 

proposed information collection should 

be sent within 30 days of publication of 

this notice to www.reginfo.gov/public/ 

do/PRAMain. Find this particular 

information collection by selecting 

‘‘Currently under 30-day Review—Open 

for Public Comments’’ or by using the 

search function. Direct written 

comments and/or suggestions regarding 

the items contained in this notice to the 

Attention: CDC Desk Officer, Office of 

Management and Budget, 725 17th 

Street NW, Washington, DC 20503 or by 

fax to (202) 395–5806. Provide written 

comments within 30 days of notice 

publication. 

Proposed Project 

Factors Influencing the Transmission 

of Influenza (OMB Control No. 0920– 

0888, Exp. 2/28/21)—Extension— 

National Institute for Occupational 

Safety and Health (NIOSH), Centers for 

Disease Control and Prevention (CDC). 

Background and Brief Description 

The National Institute for 

Occupational Safety and Health 

(NIOSH) is authorized to conduct 

research to advance the health and 

safety of workers under Section 20(a)(1) 

of the 1970 Occupational Safety and 

Health Act. NIOSH is requesting an 

extension to an existing ICR (Expiration 

Date: February 28, 2021) because the 

ongoing COVID–19 pandemic 

temporarily halted the study in 2020 

due to staff safety concerns and an 

inability to access healthcare facilities 

in order to recruit test subjects. 

Influenza continues to be a major 

public health concern because of the 

substantial health burden from seasonal 

influenza and the potential for a severe 

pandemic. Although influenza is known 

to be transmitted by infectious 

secretions, these secretions can be 

transferred from person to person in 

many different ways, and the relative 

importance of the different pathways is 

not known. The likelihood of the 

transmission of influenza virus by small 

infectious airborne particles produced 

during coughing and breathing is 

particularly unclear. The question of 

airborne transmission is especially 

important in healthcare facilities, where 

influenza patients tend to congregate 

during influenza season, because it 

directly impacts the infection control 

and personal protective measures that 

should be taken by healthcare workers. 

The purpose of this study is to gain 

a better understanding of the production 

of infectious aerosols by patients with 

influenza, and to compare this to the 

levels of biomarkers of influenza 

infection in the blood of these patients. 

To do this, airborne particles produced 

by volunteer subjects with influenza 

will be collected and tested for 

influenza virus, and the levels of 

influenza infection-associated 

biomarkers will be measured in blood 

samples from these subjects. 

Volunteer adult participants will be 

recruited by a test coordinator using a 

poster and flyers describing the study. 

Interested potential participants will be 

screened verbally to verify that they 

have influenza-like symptoms and that 

they do not have any medical 

conditions that would preclude their 

participation. A matching number of 

healthy control participants will also be 

recruited. Qualified participants who 

agree to participate in the study will be 

asked to read and sign an informed 

consent form, and then to complete a 

short health questionnaire. After 

completing the forms, the participant’s 

oral temperature will be measured and 

two nasopharyngeal mucus samples and 

five ml of blood will be collected. The 

participant then will be asked to don an 

elastomeric mask and breathe and cough 

normally for 40 minutes into an aerosol 

particle collection system. The total 

time from initial verbal screening to 

completion will be about 95 minutes. 

The study will require 90 volunteer test 

subjects each year for three years, for a 

total of 270 test participants. There are 

no changes to data collection 

instruments, methodology, or burden 

estimates. OMB approval is requested 

for three years. Participation is 

voluntary and there are no costs to 

respondents other than their time. The 

total estimated annualized burden hours 

are 148. 

ESTIMATED ANNUALIZED BURDEN HOURS

Type of respondents Form name Number of 

respondents 

Number of 

responses per 

respondent 

Avg. burden 

per response 

(in hrs.) 

Potential participant ........................................ Initial verbal screening ................................... 180 1 3/60 

Qualified participant ........................................ Informed consent form ................................... 90 1 15/60

Qualified participant ........................................ Health questionnaire ...................................... 90 1 5/60 

Qualified participant ........................................ Medical testing ............................................... 90 1 72/60 

Jeffrey M. Zirger, 

Lead, Information Collection Review Office, 

Office of Scientific Integrity, Office of Science, 

Centers for Disease Control and Prevention. 

[FR Doc. 2021–03556 Filed 2–22–21; 8:45 am] 

BILLING CODE 4163–18–P